Handheld Pulse Co-Oximeter Radical-7® Adult / Infant / Pediatric

Features

• The Masimo 9500 Kit includes the Radical-7 device and a pulse ox (SpO2) patient cable. Pulse oximetry sensors must be purchased separately.
• The Radical-7 must be docked to either a Radical docking station (PN 9021 or 9023) or the ROOT patient monitor (PN 9695 or 9515) for battery charging. ROOT allows for expanded monitoring capabilities - Brain Function Monitoring, End-Tidal CO2 (EtCO2), and Regional Oximetry (O3)
• Masimo SET Pulse Oximetry is shown to have unrivaled accuracy and reliability in more than 100 clinical studies. It is the primary pulse oximetry at all top 10 U.S. hospitals (as of 2024) and monitors more than 200 million patients a year globally.
• Accurate During Motion. Before Masimo SET® pulse oximetry, false alarm rates were high, often due to motion and low perfusion. With Masimo SET®, the rate of false alarms dropped by more than 80% and yet true alarm detection improved significantly.
• Accurate During Low Perfusion. A recent peer-reviewed study found that for Masimo SET® SpO2, ARMS* accuracy was “1.37% in all subjects with normal perfusion and 1.64% in all subjects with low perfusion.%XE2%X80?
• Accurate on All Skin Tones. A peer-reviewed publication demonstrated that Masimo RD SET sensors had only a 0.15% difference in bias between dark- and light-skinned subjects, which is not clinically significant because pulse oximeters only measure in whole numbers. Further analysis showed that RD SET accurately measured SpO2 for both Black and White subjects not only when perfusion was normal but also during low perfusion.
• Masimo SET® saves lives. A study conducted over 10 years on general floor patients being monitored with Masimo SET® while recovering from surgery found zero preventable deaths or brain damage from opioid-induced respiratory depression. Another study has shown that use of SET® led to an 80% reduction in the rate of retinopathy of prematurity (ROP, an eye disorder that can cause blindness in premature babies). Of particular note, in multiple studies, involving more than 300,000 newborns, use of SET® as part of screening for critical congenital heart disease (CCHD) has been shown to significantly improve screening sensitivity.